Valuation: Aprea Therapeutics, Inc.

Market Cap 64.59L 57.95L 53.58L 48.53L 90.66L 62Cr 91.75L 6.41Cr 2.55Cr 32Cr 2.42Cr 2.37Cr 102.2Cr P/E 2026 *
-1.53x
P/E 2027 * -1.42x
Enterprise Value 64.59L 57.95L 53.58L 48.53L 90.66L 62Cr 91.75L 6.41Cr 2.55Cr 32Cr 2.42Cr 2.37Cr 102.2Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
83.56%
Yield 2026 *
-
Yield 2027 * -
14/10 Ladenburg Thalmann Initiates Aprea Therapeutics at Buy With $2 Price Target MT
29/08 Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs CI
12/08 Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
12/08 Wedbush Adjusts Aprea Therapeutics Price Target to $3 From $6, Maintains Outperform Rating MT
30/07 Aprea Therapeutics, Inc. Provides Update On ACESOT-1051 Program For WEE1 Inhibitor APR-1051 And Expands Clinical Development CI
16/05 Aprea Therapeutics - files for resale of up to 5.5 million shares by selling stockholders - SEC filing RE
14/05 Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating MT
13/05 Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/05 Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target MT
31/03 Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc CI
31/03 Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investors CI
30/03 Aprea Therapeutics Announces Positive Emerging Clinical Activity for Wee1 Inhibitor Apr-1051 with Confirmed Partial Response in Ongoing Phase 1 Acesot-1051 Trial CI
30/03 Aprea Therapeutics highlights positive emerging clinical activity for WEE1 inhibitor, APR-1051 RE
1 day+4.29%
1 week-4.27%
Current month-28.48%
1 month-28.65%
3 months-12.60%
6 months-35.91%
Current year-37.12%
1 week 0.41
Extreme 0.41
0.56
1 month 0.41
Extreme 0.41
0.82
Current year 0.41
Extreme 0.41
1.49
1 year 0.41
Extreme 0.41
1.49
3 years 0.41
Extreme 0.41
8.85
5 years 0.41
Extreme 0.41
25.8
10 years 0.41
Extreme 0.41
25.8
Manager TitleAgeSince
Chief Executive Officer 57 29/06/2022
Director of Finance/CFO 62 30/01/2023
Corporate Officer/Principal 58 01/11/2023
Director TitleAgeSince
Director/Board Member 69 01/01/2015
Director/Board Member 65 01/08/2019
Chairman 63 23/08/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/06/26 Free

Director

15,690 0.1267%
31/03/26 Buy

Chairman

2,47,830 2.1642%
31/03/26 Buy

Chief Financial Officer

61,956 0.5410%
Change 5-day change 1-year change 3-year change Capi.($)
+4.56%-4.27%-62.23%-85.00% 64.59L
+0.65%-3.56%+33.53%+60.50% 6.35TCr
+1.76%+1.27%+11.82%+82.12% 5.45TCr
-0.94%+0.99%+10.45%+102.18% 5.36TCr
+2.06%+0.19%+27.06%+56.44% 4.48TCr
+2.21%-3.56%+17.63%+99.73% 4.16TCr
+0.84%-3.73%+221.52%+919.24% 3.99TCr
+0.64%-3.85%+11.71%+45.57% 3.25TCr
+29.06%+47.63%+107.12%+94.27% 2.67TCr
+3.72%-7.45%+24.25%-2.99% 2.34TCr
Average +4.42%-1.23%+40.29%+137.21% 3.8TCr
Weighted average by Cap. +3.11%-0.29%+47.12%+160.57%

Financials

2026 *2027 *
Net sales - -
Net income -1.61Cr -1.44Cr -1.33Cr -1.21Cr -2.26Cr -153.03Cr -2.28Cr -16Cr -6.35Cr -80Cr -6.03Cr -5.9Cr -254.21Cr -2.25Cr -2.02Cr -1.87Cr -1.69Cr -3.16Cr -214.45Cr -3.2Cr -22Cr -8.89Cr -112.22Cr -8.45Cr -8.27Cr -356.25Cr
Net Debt - -
Projected Income Statement - Annual - Aprea Therapeutics, Inc.
Logo Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Employees
-
Date Price Change Volume
29/26/29 $0.5364 +4.56% 1,39,637
27/26/27 $0.5130 +14.25% 1,87,912
26/26/26 $0.4490 -13.27% 5,68,671
23/26/23 $0.5177 -4.41% 89,183
22/26/22 $0.5416 -3.34% 1,30,055
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Aprea Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.5130USD
Average target price
3.300USD
Spread / Average Target
+543.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Aprea Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. APRE Stock